Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Makoto Kakara"'
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1543-1553 (2021)
Abstract Clinical trials for pediatric indications and new pediatric drugs face challenges, including the limited blood volume due to the patients’ small bodies. In Japan, the Evaluation Committee on Unapproved or Off‐labeled Drugs with High Medi
Externí odkaz:
https://doaj.org/article/2925bc9e8cec4b3eaa08a38fd235779e
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1543-1553 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1543-1553 (2021)
Clinical trials for pediatric indications and new pediatric drugs face challenges, including the limited blood volume due to the patients’ small bodies. In Japan, the Evaluation Committee on Unapproved or Off‐labeled Drugs with High Medical Needs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1274e86e3b6d7516047dc031586c868b
https://doi.org/10.1111/cts.13018
https://doi.org/10.1111/cts.13018
Autor:
Makoto Kakara, Masaaki Hirakawa, Kanae Higuchi, Takeshi Hirota, Yushi Kashihara, Daiki Yamashita, Ichiro Ieiri
Publikováno v:
Therapeutic Drug Monitoring. 41:674-680
Background Fosphenytoin, the diphosphate ester salt of phenytoin, is widely used to treat status epilepticus. The aim of this study was to develop a population pharmacokinetic (PPK) model to describe serum phenytoin concentrations after the intraveno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bc616e74b487233620392406fc9275
https://doi.org/10.1097/ftd.0000000000000651
https://doi.org/10.1097/ftd.0000000000000651
Autor:
Mari Shiomi, Kajal B. Larson, Matthew L. Rizk, Makoto Kakara, Hiroyuki Yoshitsugu, Hwa-Ping Feng
Publikováno v:
Journal of Infection and Chemotherapy. 25:182-191
Tazobactam/ceftolozane is a combination of a β-lactamase inhibitor and a cephalosporin antibiotic, with recommended dosage for patients with normal renal function of tazobactam 0.5 g/ceftolozane 1 g administered as a 1-h intravenous infusion every 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3f3e5a72f948f7e8182440a4564dc2c
https://doi.org/10.1016/j.jiac.2018.11.005
https://doi.org/10.1016/j.jiac.2018.11.005
Autor:
Hiroko Nomura, Mai Ezaki, Takeshi Hirota, Makoto Kakara, Sunao Matsubayashi, Masato Fukae, Ichiro Ieiri, Masaaki Hirakawa
Publikováno v:
Journal of Diabetes and its Complications. 30:1282-1286
Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdab2e98b0d40dc3450b8f865f16d35f
https://doi.org/10.1016/j.jdiacomp.2016.06.009
https://doi.org/10.1016/j.jdiacomp.2016.06.009
Autor:
Shota Muraki, Ichiro Ieiri, Takeshi Hirota, Makoto Kakara, Hiroyuki Inoue, Yoko Tamaki, Yushi Kashihara
Publikováno v:
British journal of clinical pharmacology. 85(2)
Aims The aim of the present study was to quantitate the hypoglycaemic effects of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1r) and sodium glucose cotransporter 2 inhibitors (SGLT2i) as add-on treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cce80b7e563b9c012e77d27c8b50a38
https://pubmed.ncbi.nlm.nih.gov/30394576
https://pubmed.ncbi.nlm.nih.gov/30394576
Autor:
Ryoko Kinoshita, Kunio Maema, Makoto Kakara, Yoko Tamaki, Shota Muraki, Ichiro Ieiri, Takeshi Hirota, Yushi Kashihara, Masato Fukae
Publikováno v:
Drug metabolism and pharmacokinetics. 33(6)
The objective of the present study was to develop a population pharmacodynamic (PPD) model to describe the glycated hemoglobin (HbA1c)-lowering effects of metformin in type 2 diabetes mellitus patients with and without secondary failure and to charac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c273ad2128eb6868f081ef0c2c68e13d
https://pubmed.ncbi.nlm.nih.gov/30360949
https://pubmed.ncbi.nlm.nih.gov/30360949
Autor:
Ichiro Ieiri, Saki Shigematsu, Hiroshi Takane, Daiki Yamashita, Kuniaki Moriki, Masaaki Hirakawa, Takeshi Hirota, Shota Muraki, Masato Fukae, Makoto Kakara, Miki Shimada
Publikováno v:
Journal of clinical pharmacology. 58(3)
The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)-lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1e8eceec1046214495056a3ecb5b2b1
https://pubmed.ncbi.nlm.nih.gov/29045766
https://pubmed.ncbi.nlm.nih.gov/29045766
Autor:
Hiroko Nomura, Hideki Shimomura, Ichiro Ieiri, Sunao Matsubayashi, Masato Fukae, Makoto Kakara, Takeshi Hirota, Keisuke Gotanda, Masaaki Hirakawa
Publikováno v:
British Journal of Clinical Pharmacology. 78:824-835
Aims HMG-CoA reductase inhibitors are available for use in low density lipoprotein-cholesterol (LDL-C) lowering therapy. The purposes of this study were to develop a population pharmacodynamic (PPD) model to describe the time course for the LDL-C low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::994a441120547ae1db9d4071b4190ed0
https://doi.org/10.1111/bcp.12405
https://doi.org/10.1111/bcp.12405
Autor:
Kanae Higuchi, Daiki Yamashita, Yushi Kashihara, Makoto Kakara, Takeshi Hirota, Masaaki Hirakawa, Ichiro Ieiri
Publikováno v:
Therapeutic Drug Monitoring; Oct2019, Vol. 41 Issue 5, p674-680, 7p